कृपया अन्य खोज का प्रयास करें
Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson’s disease (PD). Its lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein for the treatment of PD and other neurodegenerative diseases. The company was incorporated in 2008 and is based in Espoo, Finland.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Seppo Kaakkola | - | - | Member of Scientific Advisory Board |
Alan Whone | - | - | Member of Scientific Advisory Board |
Mart Saarma | - | - | Member of Scientific Advisory Board |
Kari Alitalo | - | - | Member of Scientific Advisory Board |
Timo Ilari Veromaa | 61 | 2012 | Independent Chairman of the Board |
Aki Pellervo Prihti | - | 2014 | Director |
Anders Gersel Pedersen | 72 | 2021 | Chairman of Scientific Advisory Board |
Frans Gustaf Wuite | - | 2014 | Director |
Hilde Furberg | 65 | 2021 | Director |
Alberto J Espay | - | 2021 | Member of Scientific Advisory Board |
Daniele Bravi | - | 2021 | Member of Scientific Advisory Board |
Mats Thoren | 52 | 2020 | Director |
David Dexter | - | 2021 | Member of Scientific Advisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है